COMPANY

 

Synthonics is a specialty pharmaceutical company engaged in the development of metal coordinated pharmaceuticals--a new generation of patentable therapeutic compounds created by covalently binding minute quantities of metals to known pharmaceutical agents. 

 

Synthonics uses its novel metal coordination chemistry to modify specific attributes of validated drug molecules. In its simplest application, metal coordination can improve a drug's performance by increasing its effective bioavailability, reducing its variability of absorption and hastening or sustaining its release in the body. By improving the absorption of already approved molecules without changing their mechanisms of action, Synthonics can create a deep portfolio of novel drug candidates with potential for best-in-class efficacy and safety at greatly reduced research and development risk, time and expense.  

 

In addition, metal coordination can increase the stability of biologic drugs and the solubility of lipophilic drugs at normal pH to permit their intravenous delivery. Advanced applications of metal coordinated pharmaceuticals permit targeted and synergistic delivery of multiple drugs to specific cells or tissues.

 

The Company has identified over 400 drug candidates that can form stable metal complexes and is currently working on improving the performance of several drug products. It has demonstrated that metal coordination chemistry could significantly improve the efficacy of drugs that are used in a variety of prevalent disease states including hypertension, erectile dysfunction, neonatal seizures, and Parkinson's disease.

 

MCPs represent a new generation of pharmaceuticals. Metal coordination can be used to create innovative and distinct versions of existing or patent-expiring pharmaceuticals, and could be profitably applied to once promising drug candidates that had been abandoned due to issues regarding safety, instability, efficacy, or problems with drug delivery.